Additive effects of rapamycin and aspirin on dendritic cell allostimulatory capacity

References

• Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature 1959;183:1682–1683
   PubMed Web of Science ®Google Scholar
• Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004;4:24–34
   PubMed Web of Science ®Google Scholar
• Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev 2010;234:5–17
   PubMed Web of Science ®Google Scholar
• Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev 2010;234:45–54
   PubMed Web of Science ®Google Scholar
• Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769–779
   PubMed Web of Science ®Google Scholar
• Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010;108:111–165
   PubMed Web of Science ®Google Scholar
• Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. Immunol Rev 2010;234:317–334
   PubMed Web of Science ®Google Scholar
• Pletinckx K, Döhler A, Pavlovic V, Lutz MB. Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T cells. Front Immunol 2011;2:39
   Google Scholar
• Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213–1222
   PubMed Web of Science ®Google Scholar
• Fu F, Li Y, Qian S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996;62:659–665
   PubMed Web of Science ®Google Scholar
• Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000;30:1813–1822
   PubMed Web of Science ®Google Scholar
• Peche H, Trinite B, Martinet B, et al. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant 2005;5:255–267
   PubMed Web of Science ®Google Scholar
• Hackstein H, Morelli AE, Thomson AW. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol 2001;22:437–442
   PubMed Web of Science ®Google Scholar
• Thomson AW, Zhang L. New partners for tolerogenic dendritic cells. Am J Transplant 2011;11:2003–2004
   PubMed Web of Science ®Google Scholar
• Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999;162:6473–6481
   PubMed Web of Science ®Google Scholar
• Matasic R, Dietz AB, Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 2000;101:53–60
   PubMed Web of Science ®Google Scholar
• Hackstein H, Morelli AE, Larregina AT, et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 2001;166:7053–7062
   PubMed Web of Science ®Google Scholar
• Buckland M, Jago CB, Fazekasova H, et al. Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am J Transplant 2006;6:2046–2059
   PubMed Web of Science ®Google Scholar
• Buckland M, Lombardi G. Aspirin and the induction of tolerance by dendritic cells. Handb Exp Pharmacol 2009;188:197–213
   PubMedGoogle Scholar
• Hernandez A, Burger M, Blomberg BB, et al. Inhibition of NF-KappaB during human dendritic cell differentiation generates anergy and regulatory T cell activity for one – but not two – HLA-DR mismatches. Hum Immunol 2007;68:715–729
   PubMed Web of Science ®Google Scholar
• Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009;9:324–337
   PubMed Web of Science ®Google Scholar
• Fischer R, Turnquist HR, Taner T, Thomson AW. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol 2009;188:215–232
   PubMedGoogle Scholar
• Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005;5:228–236
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Sumpter TL, Tsung A, et al. IL-1γ-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol 2008;181:62–72
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007;178:7018–7031
   PubMed Web of Science ®Google Scholar
• Macedo C, Turquist H, Metes D, Thomson AW. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res 2012;1:16
   PubMedGoogle Scholar
• Steinbrink K, Wölfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772–4780
   PubMed Web of Science ®Google Scholar
• Piemonti L, Monti P, Sironi M, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000;164:4443–4451
   PubMed Web of Science ®Google Scholar
• Downing I, MacDonald SL, Atkinson AP, et al. Drug modification of LPS-stimulated human monocyte-derived dendritic cells. Br J Biomed Sci 2012;69:126–133
   PubMed Web of Science ®Google Scholar
• Anderson AE, Swan DJ, Sayers BL, et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009;85:243–250
   PubMed Web of Science ®Google Scholar
• Golshayan D, Wyss JC, Buckland M, et al. Differential role of naïve and memory CD4 T-cell subsets in primary alloresponses. Am J Transplant 2010;10:1749–1759
   PubMed Web of Science ®Google Scholar
• Moreau A, Varey E, Bériou G, et al. Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials. Front Immunol 2012;3:218
   Google Scholar
• Insel PA. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, and Taylor P, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 1993, p. 638
   Google Scholar
• Day RO, Furst DE, Graham GG, Champion GD. The clinical pharmacology of aspirin and the salicylates. In: Paulus HE, Furst DE, and Dromgoole SH, eds. Drugs for rheumatic disease. New York: Churchill Livingstone; 1987, p. 227
   Google Scholar
• Chang CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002;3:237–243
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–1061
   PubMed Web of Science ®Google Scholar
• Vieira PL, Christensen JR, Minaee S, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004;172:5986–5993
   PubMed Web of Science ®Google Scholar
• Govender L, Pascual M, Golshayan D. Potential and limitations of regulatory T-cell therapy in solid organ transplantation. Expert Rev Clin Immunol 2014;10:1197–1212
   PubMed Web of Science ®Google Scholar